- Home
- KAVL vs ALBT Comparison
KAVL vs ALBT Comparison
Compare KAVL & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- ALBT
- Stock Information
- Founded
- KAVL 1998
- ALBT 2014
- Country
- KAVL United States
- ALBT United States
- Employees
- KAVL N/A
- ALBT N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KAVL Health Care
- ALBT Health Care
- Exchange
- KAVL Nasdaq
- ALBT Nasdaq
- Market Cap
- KAVL 7.9M
- ALBT 7.9M
- IPO Year
- KAVL N/A
- ALBT N/A
- Fundamental
- Price
- KAVL $0.54
- ALBT $4.80
- Analyst Decision
- KAVL
- ALBT
- Analyst Count
- KAVL 0
- ALBT 0
- Target Price
- KAVL N/A
- ALBT N/A
- AVG Volume (30 Days)
- KAVL 93.7K
- ALBT 83.2K
- Earning Date
- KAVL 04-15-2025
- ALBT 05-30-2025
- Dividend Yield
- KAVL N/A
- ALBT N/A
- EPS Growth
- KAVL N/A
- ALBT N/A
- EPS
- KAVL N/A
- ALBT N/A
- Revenue
- KAVL $3,877,695.00
- ALBT $486,815.00
- Revenue This Year
- KAVL N/A
- ALBT N/A
- Revenue Next Year
- KAVL N/A
- ALBT N/A
- P/E Ratio
- KAVL N/A
- ALBT N/A
- Revenue Growth
- KAVL N/A
- ALBT N/A
- 52 Week Low
- KAVL $0.52
- ALBT $2.11
- 52 Week High
- KAVL $9.69
- ALBT $21.60
- Technical
- Relative Strength Index (RSI)
- KAVL 34.16
- ALBT 44.79
- Support Level
- KAVL $0.52
- ALBT $5.18
- Resistance Level
- KAVL $0.60
- ALBT $7.89
- Average True Range (ATR)
- KAVL 0.05
- ALBT 0.54
- MACD
- KAVL 0.02
- ALBT -0.17
- Stochastic Oscillator
- KAVL 31.60
- ALBT 5.03
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.